Drug
Ifidancitinib clinical trials
Also written ATI-50002.
- studies test it
- 7
- open now
- 0
- in phase 3
- 0
- first study started
- 2017
How studies write it
Studies that test it under each name
Studies by the year they started
7 studies that test it; most in 2018 (4)
| Year | Studies |
|---|---|
| 2017 | 2 |
| 2018 | 4 |
| 2019 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 2
- 7
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 7 · Other 0
Related medicines
As reviewed, each with the page that says it.
- One of Janus Kinase Inhibitors source
- One of Protein Kinase Inhibitors source
- One of Tyrosine Kinase Inhibitors source
Studies
Open first, then newest update. How each study uses ifidancitinib is read from its arms, and is right about nine times in ten.
Testing it · 7
- A Study in Male and Female Subjects With Androgenetic Alopecia Treated With ATI-50002 Topical SolutionCompletedPhase 2Aclaris Therapeutics, Inc.NCT03495817Written as ATI-50002
- A Study of ATI-50002 Topical Solution for the Treatment of VitiligoCompletedPhase 2Aclaris Therapeutics, Inc.NCT03468855Written as ATI-50002 topical solution
- ATI-502 Topical Solution for the Treatment of Alopecia Areata (AA), Alopecia Universalis (AU) and Alopecia Totalis (AT)TerminatedPhase 2Aclaris Therapeutics, Inc.NCT03759340Written as ATI 502 0.46% Topical Solution
- Safety and Pharmacokinetic Study of ATI-50002 in Subjects With Alopecia Universalis (AU) and Alopecia Totalis (AT)CompletedPhase 2Aclaris Therapeutics, Inc.NCT03315689Written as ATI-50002
- A Study of ATI-50002 Topical Solution for the Treatment of Alopecia AreataTerminatedPhase 2Aclaris Therapeutics, Inc.NCT03354637Written as ATI-50002 high dose
- A Study of ATI-502 Topical Solution for the Treatment of Atopic DermatitisCompletedPhase 2Aclaris Therapeutics, Inc.NCT03585296Written as ATI-502
- Open Label Study of ATI-50002 Topical Solution Administered to Adult Subjects With Eyebrow Loss Due to Alopecia AreataCompletedPhase 2Aclaris Therapeutics, Inc.NCT03551821Written as ATI-50002
Codes
What other systems call ifidancitinib · ClinicalTrials.gg INT017742
- UNII (FDA) R105E71J13IFIDANCITINIBConfirmed FDA, Wikidata
- Wikidata Q105336999ifidancitinibConfirmed FDA, Wikidata
- NCI Thesaurus C174905IfidancitinibOne source FDA
- DrugBank DB16191One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | R105E71J13 | IFIDANCITINIB | Confirmed FDA, Wikidata |
| Wikidata | Q105336999 | ifidancitinib | Confirmed FDA, Wikidata |
| NCI Thesaurus | C174905 | Ifidancitinib | One source FDA |
| DrugBank | DB16191 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.